Contact Us: 01282 426380
KM Financial Solutions | Regeneron/Sanofi heart drug succeeds in major trial; Will insurers pay?
11859
post-template-default,single,single-post,postid-11859,single-format-standard,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,hide_top_bar_on_mobile_header,qode-child-theme-ver-1.0.0,qode-theme-ver-11.2,qode-theme-bridge,wpb-js-composer js-comp-ver-5.2.1,vc_responsive
 

Regeneron/Sanofi heart drug succeeds in major trial; Will insurers pay?

09 Mar Regeneron/Sanofi heart drug succeeds in major trial; Will insurers pay?

Posted at 14:00h in News by
0 Likes
March 10 (Reuters) – A potent, expensive cholesterol drug
sold by Regeneron Pharmaceuticals and Sanofi
significantly reduced major adverse heart events in a huge study
presented on Saturday, but it remains to be seen whether the new
data will prompt insurers to pay for increased use of the
medicine.

No Comments

Sorry, the comment form is closed at this time.